APA (7th ed.) Citation

Hauser, S. L., Cross, A. H., Winthrop, K., Wiendl, H., Nicholas, J., Meuth, S. G., . . . Kappos, L. (2022). Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years. Multiple sclerosis, 28(10), 1576. https://doi.org/10.1177/13524585221079731

Chicago Style (17th ed.) Citation

Hauser, Stephen L., et al. "Safety Experience with Continued Exposure to Ofatumumab in Patients with Relapsing Forms of Multiple Sclerosis for Up to 3.5 years." Multiple Sclerosis 28, no. 10 (2022): 1576. https://doi.org/10.1177/13524585221079731.

MLA (9th ed.) Citation

Hauser, Stephen L., et al. "Safety Experience with Continued Exposure to Ofatumumab in Patients with Relapsing Forms of Multiple Sclerosis for Up to 3.5 years." Multiple Sclerosis, vol. 28, no. 10, 2022, p. 1576, https://doi.org/10.1177/13524585221079731.